M&A Deal Summary |
|
|---|---|
| Date | 2024-02-12 |
| Target | Cymabay Therapeutics |
| Sector | Life Science |
| Buyer(s) | Gilead Sciences |
| Deal Type | Add-on Acquisition |
| Deal Value | 4.3B USD |
| Advisor(s) | Centerview Partners Lazard (Financial) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1987 |
| Sector | Life Science |
| Employees | 17,600 |
| Revenue | 28.8B USD (2024) |
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded in 1987 and is Based in Foster City, California.
| DEAL STATS | # |
|---|---|
| Overall | 24 of 24 |
| Sector: Life Science M&A | 23 of 23 |
| Type: Add-on Acquisition M&A Deals | 20 of 20 |
| State: California M&A | 8 of 8 |
| Country: United States M&A | 17 of 17 |
| Year: 2024 M&A | 1 of 1 |
| Size (of disclosed) | 5 of 21 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-05-09 |
XinThera
San Diego, California, United States XinThera is a private biotechnology company whose mission is to develop best-in-class small molecule drugs to treat cancer and immunologic diseases. XinThera was founded in 2021 and is headquartered in San Diego, California. |
Buy | - |
